How do I count chemotherapy cycles of the VRD regimen (bortezomib, lenalidomide, dexamethasone) in multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

VRD Cycle Counting in Multiple Myeloma

VRD cycles are counted every 3 weeks (21 days), with each cycle consisting of bortezomib on days 1,8, and 15; lenalidomide on days 1-14; and dexamethasone on the days of and after bortezomib administration. 1

Standard VRD Cycle Structure

According to ESMO guidelines, the VRD regimen follows this schedule 1:

  • Bortezomib: 1.3 mg/m² subcutaneously on days 1,8, and 15
  • Lenalidomide: 25 mg orally on days 1-14
  • Dexamethasone: 20 mg on the day of and day after bortezomib (or alternatively 40 mg on days 1,8,15,22)
  • Cycle length: Repeated every 3 weeks (21 days)

This means one complete cycle = 21 days, and you count a new cycle each time you restart this 3-week schedule.

Number of Cycles by Clinical Context

For Transplant-Eligible Patients (Induction)

4-6 cycles of VRD induction are recommended before proceeding to stem cell collection 1. The evidence supports:

  • 4 cycles: Standard approach used in multiple trials 2, 3, 4
  • 6 cycles: Alternative supported by PETHEMA/GEM2012 trial showing deepening responses (70.4% VGPR or better after 6 cycles vs 55.6% after 3 cycles) 4

For Transplant-Ineligible Patients

8 cycles of VRD followed by maintenance is the typical approach 5. After 8 cycles, patients may transition to:

  • Maintenance schedule: once weekly bortezomib for 4 weeks (days 1,8,15,22) followed by 13-day rest (days 23-35) 5
  • Or lenalidomide-based maintenance

For Extended/Maintenance Therapy

After completing initial cycles, maintenance dosing changes the cycle structure 5:

  • Bortezomib: once weekly for 4 weeks (days 1,8,15,22)
  • Rest period: 13 days (days 23-35)
  • This creates 35-day maintenance cycles (not 21-day cycles)

Practical Cycle Counting Algorithm

  1. Start of Cycle 1: Day 1 when first bortezomib dose is given
  2. End of Cycle 1: Day 21 (includes 7-day rest period after day 14 lenalidomide)
  3. Start of Cycle 2: Day 22 (which becomes the new "day 1" of cycle 2)
  4. Continue counting: Each subsequent 21-day period = one additional cycle

Common Pitfalls to Avoid

Do not count cycles based on calendar months - VRD uses 21-day cycles, not monthly cycles. This differs from regimens like KRd or DRd which use 28-day cycles 1.

Do not restart cycle counting after dose modifications - If you reduce bortezomib from 1.3 mg/m² to 1.0 mg/m² or 0.7 mg/m² due to toxicity 5, you continue with the same cycle number, just at a reduced dose.

Account for treatment delays - If you hold doses due to toxicity (e.g., thrombocytopenia, neuropathy), the cycle number doesn't change until you complete that cycle's planned dosing and move to the next 21-day period 5.

Distinguish induction from maintenance cycles - After completing 8 induction cycles, if transitioning to maintenance, you may restart numbering as "maintenance cycle 1" since the schedule changes to 35-day cycles 5.

Dose Modifications Within Cycles

When toxicity occurs, hold or reduce doses but maintain the cycle structure 5:

  • Grade 3-4 non-hematologic toxicity: Hold until resolved to grade 1, then resume at reduced dose (1.3→1.0→0.7 mg/m²)
  • Peripheral neuropathy: Specific dose modification guidelines apply
  • The 21-day cycle framework remains constant even with dose adjustments

The key principle: Each 21-day period from the start of bortezomib dosing = one cycle, regardless of dose modifications or brief treatment delays within that timeframe.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.